Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
May 16, 2022
- Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
- Otsuka Ends Vadadustat Global License Deal with Akebia
May 16, 2022
- Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
- Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
May 16, 2022
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Mitsubishi Tanabe Incurs Operating Loss for 3 Years Running, Logs Write-Down on OA Drug
May 16, 2022
- Eisai Seeks to File Lecanemab in Japan, US, Europe in FY2022: CEO
May 16, 2022
- Seikagaku’s Dry Eye Drug Enters PIII in US
May 16, 2022
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Nichi-Iko Files for Debt Reorganization, Incurs Loss of Over 100 Billion Yen
May 13, 2022
- Taiho Buys Back Rights to EGFR-TKI, Inks Collab with Cullinan Oncology
May 13, 2022
- Opdivo Tops Japan Sales Ranking for 4 Months on End in April: Encise
May 13, 2022
- Japan Ethical Drug Sales Up 0.4% in March: Crecon
May 13, 2022
- Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
May 12, 2022
- Takeda Poised to Weather LOEs in Next 2 Years with 10 Growth Drivers: CEO
May 12, 2022
- Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
May 12, 2022
- Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
- Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…